Citations

Showing 10 of 108094 citations.

Lower anti‐spike levels in B‐cell‐depleted patients after convalescent plasma transfusion suggest the need for repeated doses
Focosi, Daniele , Senefeld, Jonathon W. , Joyner, Michael J. , Sullivan, David , Bloch, Evan M. , Casadevall, Arturo , Sullivan, David J , Joyner, Michael J , Senefeld, Jonathon W , Focosi, Daniele , Casadevall, Arturo , Franchini, Massimo

Mayo Clinic

British Journal of Haematology | November 7, 2022 | Volume: 200 | Issue: 2 | Pages: No page available

10.1111/bjh.18544 | PMID 36342497 Get It

Prolonged, physiologically relevant nicotine concentrations in the airways of smokers
Esther, Charles R. , O’Neal, Wanda K. , Alexis, Neil E. , Koch, Abigail L. , Cooper, Christopher B. , Raffield, Laura M. , Bowler, Russel P., Comellas, Alejandro P. , Peters, Stephen P. , Hastie, Annette T. , Ronish, Bonnie , Ortega, Victor E. , Wells, J. Michael , Halper‐Stromberg, Eitan , Rennard, Stephen I. , Boucher, Richard C. , SPIROMICS, on behalf of, Hastie, Annette T , Curtis, Jeffrey L , Ronish, Bonnie , Boucher, Richard C , Raffield, Laura M , O'Neal, Wanda K , Comellas, Alejandro P , Wells, J Michael , Barjaktarević, Igor , Curtis, Jeffrey L. , SPIROMICS, on behalf of

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | November 7, 2022 | Volume: 324 | Issue: 1 | Pages: L32-L37

10.1152/ajplung.00038.2022 | PMID 36342131 Get It

Nicotine from cigarette smoke is a biologically active molecule that has pleiotropic effects in the airway, which could play a role in smoking-induced lung disease. However, whether nicotine and its metabolites reach sustained, physiologically relevant concentrations on airway surfaces of smokers is not well defined. To address these issues, concentrations of nicotine, cotinine, and hydroxycotinine were measured by mass spectrometry (MS) in supernatants of induced sputum obtained from participants in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS), an ongoing observational study that included never smokers, former smokers, and current smokers with and without chronic obstructive pulmonary disease (COPD). A total of 980 sputum supernatants were analyzed from 77 healthy never smokers, 494 former smokers (233 with COPD), and 396 active smokers (151 with COPD). Sputum nicotine, cotinine, and hydroxycotinine concentrations corresponded to self-reported smoking status and were strongly correlated to urine measures. A cutoff of ∼8–10 ng/mL of sputum cotinine distinguished never smokers from active smokers. Accounting for sample dilution during processing, active smokers had airway nicotine concentrations in the 70–850 ng/mL (∼0.5–5 µM) range, and concentrations remained elevated even in current smokers who had not smoked within 24 h. This study demonstrates that airway nicotine and its metabolites are readily measured in sputum supernatants and can serve as biological markers of smoke exposure. In current smokers, nicotine is present at physiologically relevant concentrations for prolonged periods, supporting a contribution to cigarette-induced airway disease.
Organizing Nephrologists at the State Level
Segal, Mark S. , Sastry, Ashok, Aslam, Nabeel , Roth, David L.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | November 7, 2022 | Volume: 18 | Issue: 1 | Pages: 124-126

10.2215/cjn.09430822 | PMID 36344210 Get It

Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program
Lichtenstein, Gary R. , Bressler, Brian , Francisconi, Carlos Fernando de Magalhães, Vermeire, Séverine , Lawendy, Nervin, Salese, Leonardo , Sawyerr, Gosford, Shi, Hongjiong, Su, Chinyu , Judd, Donna T., Jones, Thomas V., Loftus, Edward V. , Loftus, Edward V , Vermeire, Séverine

Mayo Clinic

Inflammatory Bowel Diseases | November 7, 2022 | Volume: 29 | Issue: 1 | Pages: 27-41

10.1093/ibd/izac084 | PMID 36342120 Get It

Abstract Background In patients with ulcerative colitis (UC), risks of infection and malignancies increase with age. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. This analysis assessed age as a risk factor for adverse events of special interest (AESI) in the tofacitinib UC clinical program. Methods Data were from phase 2 and 3 induction studies, a phase 3 maintenance study, and an open-label, long-term extension study. Efficacy and/or safety outcomes were analyzed in the Induction, Maintenance, and Overall Cohorts (patients who received ≥ 1 dose of tofacitinib), stratified by age. The effects of baseline demographic and disease-related factors on AESI incidence were assessed by Cox proportional-hazards regression analysis. Results In the Overall Cohort (1157 patients with ≤ 6.8 years’ tofacitinib treatment), age was a statistically significant predictor of herpes zoster (HZ), malignancies excluding nonmelanoma skin cancer (NMSC), and NMSC. Other statistically significant predictors included prior tumor necrosis factor inhibitor failure for HZ, NMSC, and opportunistic infection events, and prior duration of UC for malignancies excluding NMSC. In the Induction and Maintenance Cohorts, a higher proportion of tofacitinib-treated than placebo-treated patients (numerical difference) achieved the efficacy endpoints (endoscopic improvement, clinical remission, clinical response) across all age groups. Conclusions Older individuals receiving tofacitinib as induction and maintenance therapy to treat UC may have an increased risk of HZ, malignancies (excluding NMSC), and NMSC versus similarly treated younger patients, consistent with findings from the general population. Across all age groups, tofacitinib demonstrated greater efficacy than placebo as an induction and maintenance therapy. ClinicalTrials.gov Registration Numbers NCT00787202; NCT01465763; NCT01458951; NCT01458574; NCT01470612.
Future Treatments of Diabetic Retinopathy: Pharmacotherapeutic Products Under Development
Stewart, Michael W.

Mayo Clinic

EMJ Diabetes | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: 93-103

10.33590/emjdiabet/10313575 Get It

Diabetic macular oedema (DMO) is the leading cause of vision loss in working aged individuals. Macular laser photocoagulation was the primary DMO treatment for several decades, but has recently been replaced by intravitreal injections of corticosteroids and drugs that inhibit the actions of vascular endothelial growth factor (VEGF). In Phase III trials, anti-VEGF drugs improve best corrected visual acuity by a mean of +12 letters, but up to 40% of patients have sub-optimal responses to therapy. The new anti-VEGF drugs abicipar and brolucizumab may possess extended durations of action in Phase III neovascular age-related macular degeneration trials, and DMO trials are being planned. Angiopoietin-2 inhibitors, both as co-formulations with anti-VEGF drugs and as bispecific antibodies, are in Phase II trials for DMO. Drugs that stimulate the Tie2 receptor are administered via subcutaneous injections. Intravenously administered antibodies that decrease diabetes-mediated inflammation, such as tocilizumab and teprotumumab, are entering early phase studies. Other drugs with topical (mecamylamine) and oral (minocycline) delivery routes are being developed. Several of these drugs may become available to patients within the next 5–10 years.
Lisinopril-Induced Small Bowel Angioedema: An Unusual Cause of Severe Abdominal Pain
Johnson, Brooks , Rydburg, Ann M., Viet, Duc Nguyen Hoang , Johnson, Brooks W , Do, Viet D, Do, Viet D.

Mayo Clinic

American Journal of Case Reports | November 7, 2022 | Volume: 23 | Issue: No issue available | Pages: No page available

10.12659/ajcr.937895 | PMID 36413511 Get It

The Use of Freezer Paper for Thin, Fragile Specimens in Mohs Surgery
McGuinness, Ashley E., Richey, Patricia M. , Fair, Leesa, Van Beek, Marta, Beek, Marta J. Van

Mayo Clinic

Dermatologic Surgery | November 7, 2022 | Volume: 48 | Issue: 11 | Pages: 1254-1255

10.1097/dss.0000000000003619 | PMID 36342255 Get It

Routine Donor and Recipient Screening for Mycoplasma hominis and Ureaplasma Species in Lung Transplant Recipients
Vijayvargiya, Prakhar , Garrigos, Zerelda Esquer , Kennedy, Cassie C. , Daly, Richard C. , Wylam, Mark E. , Patel, Robin , Beam, Elena , Esquer Garrigos, Zerelda , Patel, Robin , Kennedy, Cassie C , Beam, Elena

Mayo Clinic

Open Forum Infectious Diseases | November 7, 2022 | Volume: 9 | Issue: 11 | Pages: No page available

10.1093/ofid/ofac607 | PMID 36467297 Get It

Abstract Background Mycoplasma hominis, Ureaplasma urealyticum, and Ureaplasma parvum may cause post-transplant infections in lung transplant recipients. We evaluated routine pretransplant screening for these Mollicutes. Methods We retrospectively reviewed records of lung transplant recipients at our tri-site institution from 01/01/2015 to 11/15/2019. M. hominis and/or Ureaplasma polymerase chain reaction (PCR) was performed on pretransplant recipient urine specimens and donor bronchial swabs at the time of transplantation. Development of Mollicute infection and hyperammonemia syndrome (HS) was recorded. Results A total of 268 patients underwent lung transplantation during the study period, of whom 105 were screened with at least 1 Mollicute PCR. Twelve (11%) screened positive; 10 donors, 1 recipient, and 1 both. Among positive donors, 3 were positive for M. hominis, 5 for U. urealyticum, and 4 for U. parvum. Preemptive therapy included doxycycline, levofloxacin, and/or azithromycin administered for 1–12 weeks. Despite therapy, 1 case of M. hominis mediastinitis and 1 case of HS associated with Ureaplasma infection occurred, both donor-derived. Of those screened before transplant, cases with positive screening were more likely (P < 0.05) to develop Mollicute infection despite treatment (2/12, 17%) than those who screened negative (1/93, 1%). Conclusions Pretransplant recipient urine screening had a low yield and was not correlated with post-transplant Mollicute infection, likely because most M. hominis and U. parvum/urealyticum infections in lung transplant recipients are donor-derived. Routine donor bronchus swab PCR for M. hominis, U. urealyticum, and U. parvum followed by preemptive therapy did not obviously impact the overall incidence of Mollicute infection or HS in this cohort.
CEM and MR Radiomics-based Biomarkers to Predict Immunohistochemistry Breast Cancer Subtypes: A comparative study
Iquebal, Ashif Sikandar , Zhou, Siqiong , Pfeiffer, Nicholaus, Ranjbar, Sara , Banerjee, Imon , Swanson, Kristin R. , Anderson, Karen S. , Pockaj, Barbara A. , Banerjee, Imon , Swanson, Kristin R , Batalini, Felipe , Murtaza, Muhammed , Patel, Bhavika

Mayo Clinic

No container title available | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2232518/v1 Get It

Abstract Purpose Accurately predicting the clinical breast cancer subtypes could be extremely helpful for radiologists, pathologists, surgeons, and clinicians and inform future treatment prediction algorithms. Therefore, we evaluate and compare the accuracy of radiomic features extracted from contrast enhanced mammography (CEM) and magnetic resonance imaging (MRI) scans to make predictions to subtypes of breast cancer. Methods This HIPAA-compliant prospective single institution study was approved by the local institutional review board with written informed consent. Women with breast tumors 2 cm or larger underwent dynamic contrast-enhanced MRI and/or CEM for surgical staging. Semi-manual regions of interest were drawn by radiologist using Cancer Imaging Phenomics Toolkit (CaPTk). Radiomic features were obtained using PyRadiomics and MR- and CEM- based classification models were built on a low-dimensional representation of the features obtained via kernel principal component analysis. We subscribed to an ensemble tree-based learning approach called extremely randomized trees (ERT) to predict cancer subtypes captured via immunohistochemistry markers. Results For MRI analysis, 124 women with newly diagnosed breast cancer were included in the analysis comprising 49 HR+HER2-, 37 HR+HER2+, 11 HR-HER2+, and 27 HR-HER2- cases. For CEM analysis, models were built using data from 170 female patients including 74 HR+HER2-, 41 HR+HER2+, 14 HR-HER2+, and 43 HR-HER2-. CEM based model resulted in accuracies of 55%, 72%, 88%, and 71% respectively for HR+HER2-, HR+HER2+, HR-HER2+, and HR-HER2- whereas MRI based model alone led to accuracies of 54%, 62%, 89%, and 76% respectively for HR+HER2-, HR+HER2+, HR-HER2+, and HR-HER2-. Conclusions Radiomic features extracted from CEM and MR were strong predictors of breast cancer subtypes with CEM-based radiomic features performing slightly better, though not statistically significantly better (p = 0.82), than its MRI counterpart.
Advantages of CT Versus MRI for Preoperative Assessment of Osteochondritis Dissecans of the Capitellum
Müller, Sebastian A. , Müller-Lebschi, Julia A., Shotts, Ezekiel E., Bond, Jeffrey R., Collins, Mark S., Tiegs-Heiden, Christin A, O'Driscoll, Shawn W., Shotts, Ezekiel E., Tiegs‐Heiden, Christin A. , O’Driscoll, Shawn W.

Mayo Clinic

The American Journal of Sports Medicine | November 7, 2022 | Volume: 50 | Issue: 14 | Pages: 3941-3947

10.1177/03635465221129598 | PMID 36342019 Get It

Background: Magnetic resonance imaging (MRI) is considered to be the gold standard for imaging of osteochondritis dissecans (OCD). Purpose/Hypothesis: The purpose was to determine the additional value of a preoperative computed tomography (CT) scan in adolescent patients with capitellar OCD of the elbow. Consistent with the fact that OCD is a lesion involving the subchondral bone, the hypothesis was that CT would be superior to MRI for imaging OCD of the capitellum. Study Design: Cohort study (diagnosis); Level of evidence, 3. Methods: All patients being treated surgically for an OCD of the capitellum between 2006 and 2016 at one institution were reviewed for preoperative imaging. A total of 28 patients met the inclusion criteria. Corresponding MRI and CT scans were compared retrospectively. Multiple parameters were recorded, with special emphasis on OCD lesion size, fragmentation, and tilt as well as joint surface integrity, loose bodies, and osteophytes. Results: The OCD lesions were best seen on CT scans, whereas MRI T1-weighted images overestimated and T2-weighted images underestimated the size of defects. A subchondral fracture nonunion was found on CT scans in 18 patients, whereas this was seen on MRI T1-weighted images in only 2 patients ( P < .001) and MRI T2-weighted images in 4 patients ( P < .001). Fragmentation of the OCD fragment was found on CT scans in 17 patients but on MRI scans in only 9 patients ( P = .05). Osteophytes as a sign of secondary degenerative changes were seen on CT scans in 24 patients and were seen on MRI scans in 15 patients ( P = .02). Altogether, only 51 of 89 secondary changes including loose bodies, effects on the radial head and ulnohumeral joint, and osteophytes that were seen on CT scans were also seen on MRI scans ( P = .002). Conclusion: OCD fragmentation and secondary changes were more often diagnosed on CT. These factors indicate OCD instability or advanced OCD stages, which are indications for surgery. In an adolescent who is considered at risk for OCD (baseball, gymnastics, weightlifting, tennis) and who has lateral elbow joint pain with axial or valgus load bearing, CT is our imaging modality of choice for diagnosing and staging OCD of the capitellum.